Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT04848753 is registered in ClinicalTrials.gov with Shanghai Junshi Bioscience Co., Ltd. as lead sponsor.

NCT NCT04848753
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04848753 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Lead sponsor
Shanghai Junshi Bioscience Co., Ltd.
Phase
Phase 3
Overall status
Active, not recruiting
Start date
May 12, 2021
Completion date
May 12, 2027
Enrollment
663 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

resectable locally advanced thoracic esophageal squamous cell carcinoma